Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus

A technology of herpes simplex virus and health care products, which is applied in the field of medicine to achieve good market application prospects and low toxicity

Inactive Publication Date: 2019-06-28
THE AFFILIATED HOSPITAL OF QINGDAO UNIV +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no report on the effect of myricetin on simple viral infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus
  • Application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus
  • Application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: Inhibitory effect of myricetin on herpes simplex virus in vitro

[0041] 1. Experimental method

[0042] (1) Resazurin method to detect the cytotoxicity of myricetin

[0043] Cytotoxicity of myricetin in Vero, Hep-2, HeLa cells was determined by resazurin dye. Divide the cells into 1×10 4 / well was seeded in a 96-well plate at 37°C, 5% CO 2 Cultured in a constant temperature cell incubator for 24 hours, myricetin was serially diluted with serum-free medium and added to a 96-well plate, and cultured for another 24 hours. Add 20 μl of resazurin dye and incubate at 37°C for 6h. A full-wavelength multifunctional microplate reader was used to detect the absorbance at an absorption wavelength of 540 nm and an emission wavelength of 595 nm. The cell survival rate was used as the toxicity index of myricetin to different cells.

[0044] (2) Cytopathic effect (CPE) inhibition test

[0045] Antiviral activity was assessed by CPE inhibition assay. Vero cells in 9...

Embodiment 2

[0056] Example 2: Mechanism of action of myricetin against HSV

[0057] 1. Experimental method

[0058] (1) Indirect immunofluorescence test

[0059] Vero cells infected with HSV-1 or HSV-2 (MOI=1.0) were treated with myricetin (10 μM) for 8 hours at 37°C. Afterwards, cells were washed with PBS and fixed with 4% paraformaldehyde for 20 min. Cells were then permeabilized with 0.5% (v / v) Triton X-100 in PBS for 5 minutes and then incubated with 2% BSA for 1 hour at 37°C. After washing, cells were incubated with anti-ICP27 antibody (1:100 dilution) and DyLight649-conjugated secondary antibody, respectively. Nuclei were then stained with DAPI for 20 min prior to confocal imaging. Images were recorded using a Nikon confocal microscope.

[0060] (2) Real-time RT-PCR assay

[0061] Total RNA was extracted from HSV-infected Vero cells using the RNAiso™ Plus kit (Takara, Japan), and analyzed using the One Step SYBR PrimeScript RT-PCR kit (Takara, Japan). Primer pairs for HSV gD ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus. Experiments prove that the myricetin hasthe inhibitory activity on herpes simplex virus infection, has the activity of resisting HSV-1 and HSV-2, and has extremely low toxicity. The protein and mRNA expression of HSV-1 and HSV-2 were significantly inhibited by myricetin treatment. The action mechanism of the myricetin for resisting herpes simplex virus infection is that the myricetin directly interacts with HSV particles to interfere virus adsorption and virus-induced membrane fusion. Experiments prove that the myricetin can be developed into a novel target virus particle anti-HSV preparation and has good market application prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of myricetin in the preparation of medicines and health products for preventing and treating diseases caused by herpes simplex virus. Background technique [0002] Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are enveloped double-stranded DNA viruses belonging to the herpesviridae family. HSV-1 infection causes skin lesions, usually limited to the oral, nasal and ocular levels, whereas with HSV-2, infection is most commonly found in sites such as genital skin and mucous membranes. Worldwide approximately 60%-90% of adults are seropositive for HSV-2. More than 1 in 6 people in the United States have HSV-2, one of the most common sexually transmitted infections. Both HSV-1 and HSV-2 are neuroinvasive and can become latent in neurons. Current FDA-approved antiviral agents for herpes viruses mainly involve nucleoside analogs, such as acyclovir (ACV) an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P31/22A23L33/10
Inventor 郝翠王伟徐萃婧李文淼王姝垚张丽娟
Owner THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com